A new meta-analysis of more than 6000 studies shows that oral contraceptives significantly reduce the risk of ovarian cancer. The risk reduction increases proportionally with duration of use.
See the abstract here
Related Topics
OCRA’s Advocate’s Corner: May 2026
Written by Julia Thayer, Associate Director, Advocacy There have been several exciting advocacy developments in recent weeks, especially at the state level, where advocates and coalition partners continue advancing efforts to expand access to biomarker testing and improve patient care. Tennessee Becomes the 24th State with Comprehensive Biomarker Testing Coverage Earlier in May, Tennessee officially … Continued
OCRA-Funded ROCCA Platform Launches to Accelerate Rare Ovarian Cancer Research
OCRA is proud to announce the launch of the Rare Ovarian Cancer Collaborative Analytics (ROCCA) Platform, an international federated data network funded by OCRA to connect researchers globally and accelerate breakthroughs in rare ovarian cancer research. A collaborative approach to research for rare ovarian cancer ROCCA is launching with two foundational projects: one in mucinous … Continued
We’re Changing How Cancer Research Happens
We Believe There’s a Better Way to Do Research So we created it. OCRA has launched the most ambitious initiative in our history. We believe it represents a fundamentally new way for research to work—one with the potential to accelerate discovery in gynecologic cancers while serving as a model for breakthroughs across all diseases. We … Continued
